Genentech/Novartis Xolair BLA Resubmission Planned For 2002
Executive Summary
Genentech and Novartis expect to file an amended Xolair BLA in the fourth quarter of 2002
You may also be interested in...
Diovan CHF Claim: Use As Substitute For ACE Inhibitor Supported By FDA
FDA's "approvable" letter for Diovan in congestive heart failure suggests that existing data are sufficient to approve the drug as a substitute to ACE inhibitors, Novartis Pharmaceuticals Development Head Joerg Reinhardt told an Oct. 30 New York analysts meeting
Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma
Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011